This database contains 219 studies, archived under the term: "complications"
Click here to filter this large number of results.
A randomized crossover trial to study the effect of personalized, one-to-one interaction using Montessori-based activities on agitation, affect, and engagement in nursing home residents with Dementia
van der Ploeg, Eva S,
Eppingstall, Barbara,
Camp, Cameron J.,
Runci, Susannah J.,
Taffe, John,
O'Connor, Daniel W.
Background: Increasingly more attention has been paid to non-pharmacological interventions as treatment of agitated behaviors that accompany dementia. The aim of the current study is to test if personalized one-to-one interaction activities based on Montessori principles will improve agitation, affect, and engagement more than a relevant control condition.; Methods: We conducted a randomized crossover trial […]
Prevalence of anosognosia in Alzheimer’s disease
Turró-Garriga, Oriol,
Conde-Sala, Josep Lluís,
Reñé-Ramírez, Ramón,
López-Pousa, Secundino,
Gascón-Bayarri, Jordi,
Garre-Olmo, Josep
Background and Objective: Anosognosia is a disorder that affects the clinical presentation of Alzheimer’s disease (AD), increasing in frequency with the evolution of AD. The objective was to determine the prevalence of anosognosia and analyze the associated factors and predictors.; Patients and Method: Multicenter transversal and observational study of 345 AD patients. Anosognosia was assessed […]
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease
Trzepacz, Paula T.,
Cummings, Jeffrey,
Konechnik, Thomas,
Forrester, Tammy D.,
Chang, Curtis,
Dennehy, Ellen B.,
Willis, Brian A.,
Shuler, Catherine,
Tabas, Linda B.,
Lyketsos, Constantine
Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer’s disease (AD).; Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory […]
Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer’s disease
Troussière, Anne-Cécile,
Monaca Charley, Christelle,
Salleron, Julia,
Richard, Florence,
Delbeuck, Xavier,
Derambure, Philippe,
Pasquier, Florence,
Bombois, Stéphanie
Background: It is essential to detect and then treat factors that aggravate Alzheimer’s disease (AD). Here, we sought to determine whether or not continuous positive airway pressure (CPAP) therapy for sleep apnoea syndrome (SAS) slows the rate of cognitive decline in mild-to-moderate AD patients.; Methods: Between January 2003 and June 2011, we included consecutive, mild-to-moderate […]
The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study
Trollor, Julian N.,
Smith, Evelyn,
Agars, Emmeline,
Kuan, Stacey A.,
Baune, Bernhard T.,
Campbell, Lesley,
Samaras, Katherine,
Crawford, John,
Lux, Ora,
Kochan, Nicole A.,
Brodaty, Henry,
Sachdev, Perminder
Inflammation may contribute to cognitive decline and dementia. This study examined the cross-sectional relationships between markers of systemic inflammation (C-reactive protein, interleukins-1β, -6, -8, -10, -12, plasminogen activator inhibitor, serum amyloid A, tumour necrosis factor-α and vascular adhesion molecule-1) and cognitive function in 873 non-demented community-dwelling elderly participants aged 70-90 years. Regression analyses were performed […]
Differential perceptions of quality of life (QoL) in community-dwelling persons with mild-to-moderate dementia
Tay, Laura,
Chua, Kia Chong,
Chan, Mark,
Lim, Wee Shiong,
Ang, Yue Ying,
Koh, Evonne,
Chong, Mei Sian
Background: Discordance between patient- and caregiver-reported quality of life (QoL) is well recognized. This study sought to (i) identify predictors of discrepancy between patient- and caregiver-rated QoL amongst community-dwelling persons with mild-to-moderate dementia, and (ii) differentiate between patients who systematically rate their QoL lower versus those who rate their QoL higher relative to their caregiver […]
Infection hospitalization increases risk of dementia in the elderly
Tate, Judith A.,
Snitz, Beth E.,
Alvarez, Karina A.,
Nahin, Richard L.,
Weissfeld, Lisa A.,
Lopez, Oscar,
Angus, Derek C.,
Shah, Faraaz,
Ives, Diane G.,
Fitzpatrick, Annette L.,
Williamson, Jeffrey D.,
Arnold, Alice M.,
DeKosky, Steven T.,
Yende, Sachin
Objectives: Severe infections, often requiring ICU admission, have been associated with persistent cognitive dysfunction. Less severe infections are more common and whether they are associated with an increased risk of dementia is unclear. We determined the association of pneumonia hospitalization with risk of dementia in well-functioning older adults.; Design: Secondary analysis of a randomized multicenter […]
Yokukansan treatment of chronic renal failure patients receiving hemodialysis, with behavioral and psychological symptoms of dementia: an open-label study
Sumiyoshi, Hidenori,
Mantani, Akio,
Nishiyama, Satoshi,
Fujiwaki, Soh,
Ohta, Shoichiro,
Masuda, Yoshikazu,
Tomita, Youhei,
Tarumoto, Naofumi,
Yamawaki, Shigeto
Objective: The efficacy and safety of yokukansan (YKS) for chronic renal failure (CRF) patients receiving hemodialysis with behavioral and psychological symptoms of dementia (BPSD) was evaluated.; Methods: Twelve CRF patients receiving hemodialysis with BPSD were recruited and 7.5 g of YKS powder was added to ongoing therapy with antipsychotics. Neuropsychiatric Inventory (NPI) criteria and Barthel […]
Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial
Sullivan, Mark D.,
Katon, Wayne J.,
Lovato, Laura C.,
Miller, Michael E.,
Murray, Anne M.,
Horowitz, Karen R.,
Bryan, R. Nick,
Gerstein, Hertzel C.,
Marcovina, Santica,
Akpunonu, Basil E.,
Johnson, Janice,
Yale, Jean Francois,
Williamson, Jeff,
Launer, Lenore J.
Importance: Depression has been identified as a risk factor for dementia among patients with type 2 diabetes mellitus but the cognitive domains and patient groups most affected have not been identified.; Objective: To determine whether comorbid depression in patients with type 2 diabetes accelerates cognitive decline.; Design: A 40-month cohort study of participants in the […]